COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN TREATING NAMD IN CHINA

被引：0
|
作者：
Fan, C. S. [1 ]
Dai, H. [2 ]
Chen, B. B. [1 ]
Wang, F. X. [1 ]
Jiang, L. T. [1 ]
Wang, X. [3 ]
Han, R. [4 ]
Wu, J. H. [5 ]
机构：
[1] Beijing Med & Hlth Econ Res Assoc, Beijing, Peoples R China
[2] Beijing Hosp, Dept Ophthalmol, Natl Ctr Gerontol, Beijing, Peoples R China
[3] Beijing Hosp, Natl Ctr Gerontol, Beijing, Peoples R China
[4] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[5] PLA, Hosp 306, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG18
引用
收藏
页码：S599 / S600
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China
    Ming, Jian
    Zhang, Yabing
    Xu, Xun
    Zhao, Mingwei
    Wang, Yusheng
    Chen, Youxin
    Zhang, Feng
    Wang, Jiawei
    Liu, Jun
    Zhao, Xinran
    Han, Rong
    Hu, Shanlian
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (03) : 161 - 175
  • [2] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN DIABETIC MACULAR OEDEMA IN SWEDEN
    Branco, Castelo A.
    Eriksson, M.
    Nilsson, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [3] A Cost-Effectiveness Analysis of Intravitreal Aflibercept for the Prevention of Progressive Diabetic Retinopathy
    Patel, Nimesh A.
    Yannuzzi, Nicolas A.
    Lin, James
    Smiddy, William E.
    [J]. OPHTHALMOLOGY RETINA, 2022, 6 (03): : 213 - 218
  • [4] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN
    Clements, K. M.
    Hulbert, E. M.
    Panchmatia, H. R.
    Eriksson, M.
    Wittrup-Jensen, K. U.
    Nilsson, J.
    Weinstein, M. C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A506 - A506
  • [5] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT INJECTION (IAI) IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE US
    Vitti, R.
    Clements, K. M.
    Panchmatia, H.
    Hulbert, E.
    Wittrup-Jensen, K.
    Lewis, B. E.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A177 - A177
  • [6] Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
    Ferrante, Nicola
    Ritrovato, Daniela
    Bitonti, Rossella
    Furneri, Gianluca
    [J]. BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
  • [7] Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
    Nicola Ferrante
    Daniela Ritrovato
    Rossella Bitonti
    Gianluca Furneri
    [J]. BMC Health Services Research, 22
  • [8] Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
    Hernandez, Luis
    Lanitis, Tereza
    Cele, Clifford
    Toro-Diaz, Hector
    Gibson, Andrea
    Kuznik, Andreas
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 608 - 616
  • [9] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN GREECE
    Kourlaba, G.
    Tzanetakos, C.
    Datseris, J.
    Rouvas, A.
    Arzoumanidou, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [10] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA
    Ming, J.
    Zhang, Y.
    Xu, X.
    Zhao, M.
    Wang, Y.
    Chen, Y.
    Zhang, F.
    Wang, J.
    Liu, J.
    Zhao, X.
    Han, R.
    Hu, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S580 - S580
12345